Simvastatin Releases Ca2+ from a Thapsigargin-Sensitive Pool and Inhibits InsP3-Dependent Ca2+ Mobilization in Vascular Smooth Muscle Cells

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 3, 1996, Pages 383-391

  Escobales, Nelson ^a,b   Castro, Miriam ^a   Altieri, Pablo I ^b   Sanabria, Priscila ^c  

^a Departments of Physiology   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

3 hydroxy 3 methyl glutaryl coenzyme a reductase; Angiotensin II; Intracellular calcium; Simvastatin; Smooth muscle cells; Thapsigargin

Indexed keywords

ANGIOTENSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL TRISPHOSPHATE; MEVALONIC ACID; MEVINOLIN; PLATELET DERIVED GROWTH FACTOR; SIMVASTATIN; THAPSIGARGIN; VASOPRESSIN; ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN II; CALCIUM; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; HYPERCHOLESTEROLEMIA; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; CALCIUM; CALCIUM-TRANSPORTING ATPASES; CELLS, CULTURED; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INOSITOL 1,4,5-TRISPHOSPHATE; LOVASTATIN; MUSCLE, SMOOTH, VASCULAR; RATS; SIMVASTATIN; THAPSIGARGIN;

EID: 0029658755     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199603000-00011     Document Type: Article

References (40)

1. Fuster V, Badimon JJ, Badimon L. Clinical-pathological correlations of coronary disease progression and regression. Circulation 1992;86(suppl III):III1-11.
2. Ross RN. The pathogenesis of atherosclerosis-an update. N Engl J Med 1986;314:488-500.
3. Collins P, Fox K. The pathogenesis of atheroma and the rationale for its treatment. Eur Heart J 1992;13:560-5.
4. Martin JF, Hassal DG. The endothelium and atherosclerosis. In: Warren JB, ed. The endothelium: an introduction to current research. New York, Wiley-Liss, 1990:95-105.
5. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-8.
6. Waters D, Higginson L, Gladstone P, et al. Effects of mono- therapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative adenography. Circulation 1994;89:959-68.
7. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-9.
9. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992;95:87-94.
10. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25.
11. Quesney-Huneeus V, Hughes Wiley M, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979;76:5056-60.
12. + antiport activity in human fibroblasts. Am J Physiol 1991;261(Cell Physiol 30):C780-6.
13. 2+ responses in rat A10 vascular smooth muscle cells. Circ Res 1994;74:173-81.
14. Rozengurt E. Early signals in the mitogenic response. Science 1986;234:161-73.
15. Pouysségur J, Sewen K. Transmembrane receptors and intracellular pathways that control cell proliferation. Annu Rev Physiol 1992;54:195-210.
16. Soltoff SP, Cantley LC. Mitogens and ion fluxes. Annu Rev Physiol 1988;50:207-23.
17. + exchange and reduces calcium mobilization by PDGF and Angiotensin II in vascular smooth muscle cells [Abstract]. FASEB J 1994; 8:A569.
18. Travo P, Barret G, Burnstock G. Differences in proliferation of primary cultures of vascular smooth muscle cells taken from male and female rats. Blood Vessels 1980;17:110-6.
19. Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA, Alexander RW. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 1986; 261:5901-6.
20. Grynkiewicz G, Poenie M, Tsien RY. A new generation of calcium indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-50.
21. Downes CP, Michell RH. Phosphoinositide phosphodi-esterase of erythrocytes membranes. Biochem J 1981;198: 133-40.
22. 2+ ATPase. Proc Natl Acad Sci USA 1990;87: 2466-70.
23. Putney JW Jr. Inositol phosphates and calcium entry. Adv Second Messenger Phosphoprotein Res 1992;26:143-60.
24. Smith JB. Angiotensin-receptor signaling in cultured vascular smooth muscle cells. Am J Physiol 1986;(Renal Fluid Electrolyte Physiol 19):F759-69.
25. Kondo T, Konishi F, Inui H, Inagami T. Differing signal transductions elicited by three isoforms of platelet-derived growth factor in vascular smooth muscle cells. J Biol Chem 1993;268:4458-64.
26. 2+ buffering and coupling to AVP-evoked inositol phosphate synthesis. Am J Physiol 1994;266(Cell Physiol 35):C276-83.
27. Fairbanks KP, White LD, Goodman DS. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 1984;259:1546-51.
28. Habenicht AJ, Glomset JA, Russel R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980;255:5134-40.
29. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
30. Missiaen L, De Smedt H, Droogmans G, Himpens B, Cast-eels R. Calcium ion homeostasis in smooth muscle. Pharmacol Ther 1992;56:191-231.
31. Vickers S, Duncan CA, Wu Chen I, Rosegay A, Duggan DE. Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138-45.
32. Germershausen JI, Hunt VM, Bostedor RG, et al. Tissue selectivity of the cholesterol lowering agents lovastatin. simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 1989;158:667-75.
33. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993;69: S30-7.
34. Nomoto A, Mutoh S, Hagihara H, Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nivadipine. Atherosclerosis 1988;72:213-9.
35. Yang Z, Noll G, Luscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation 1993;88:832-6.
36. Hadeishi H, Mayberg MR, Seto M. Local application of calcium antagonists inhibit intimal hyperplasia after arterial injury. Neurosurgery 1994;34:114-21.
37. i in vascular smooth muscle cells. Circ Res 1993;73:118-24.
38. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18:(suppl II):II100-5.
39. 2+ transients are not required for platelet-derived growth factor to induce cell cycle progression of vascular smooth muscle cells in primary culture. J Biol Chem 1994;269:9011-8.
40. Ghosh TK, Bian J, Short AD, Rybak SL, Gill DL. Persistent intracellular calcium pool depletion by thapsigargin and its influence on cell growth. J Biol Chem 1991;266:24690-7.